vitamin-k-semiquinone-radical and buflomedil

vitamin-k-semiquinone-radical has been researched along with buflomedil* in 1 studies

Trials

1 trial(s) available for vitamin-k-semiquinone-radical and buflomedil

ArticleYear
The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants.
    Thrombosis research, 1995, Jun-15, Volume: 78, Issue:6

    Deep venous thromboses can be divided into two groups according to their pathogenesis, anatomical features and differing responses to therapy. The first and most frequent consists of so-called simple venous thrombosis while the second group, which is less common, comprises severe or recurrent venous thrombosis characterised by a multifactorial pathogenesis, a mixed thrombus rich in platelets and by an incomplete response to both prophylactic and therapeutic treatment with anticoagulants (heparin or vitamin K antagonist). In a randomized, prospective blind study in patients with severe or recurrent venous thrombosis, which included 6 groups each of 100 patients, co-administration of anticoagulants with various types of antiplatelet agent, either with rheological effects (piracetam, buflomedil, pentoxifylline) or without them (dipyridamole), has shown a beneficial potentiating antithrombotic effect with those drugs possessing rheological effects and the absence of this effect with dipyridamole.

    Topics: Adult; Anticoagulants; Biomarkers; Blood Coagulation Tests; Blood Viscosity; Dipyridamole; Drug Therapy, Combination; Female; Hemorheology; Heparin; Humans; Male; Middle Aged; Pentoxifylline; Piracetam; Platelet Aggregation Inhibitors; Pyrrolidines; Recurrence; Severity of Illness Index; Single-Blind Method; Treatment Outcome; Venous Thrombosis; Vitamin K

1995